Literature DB >> 11878574

Analysis of TP53 mutations in relapsed childhood acute lymphoblastic leukemia.

J Gump1, L McGavran, Q Wei, S P Hunger.   

Abstract

TP53 is the most commonly mutated gene in human cancer, but TP53 mutations are present in less than 5% of children with acute lymphoblastic leukemia (ALL) at initial presentation. Mutations are detected more frequently in children with relapsed T-cell ALL, but the potential role of TP53 mutations in relapsed B-lineage childhood ALL is not understood as well. The authors determined the nucleotide sequence of amplified DNA from exons 5 to 8 of the TP53 gene in leukemic cells obtained from 17 children with ALL at the time of first bone marrow relapse. All 17 contained only germline TP53 sequences. Review of the published literature disclosed that TP53 mutations have been found in 22% of cases of relapsed ALL. To understand the role of p53 abnormalities in this clinical setting, it will be important for future studies to analyze cases of relapsed ALL with assays capable of interrogating the functional integrity of the p53 pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11878574     DOI: 10.1097/00043426-200110000-00005

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  7 in total

Review 1.  Genomic profiling of B-progenitor acute lymphoblastic leukemia.

Authors:  Charles G Mullighan
Journal:  Best Pract Res Clin Haematol       Date:  2011-11-06       Impact factor: 3.020

2.  WT1 mutations in T-ALL.

Authors:  Valeria Tosello; Marc R Mansour; Kelly Barnes; Maddalena Paganin; Maria Luisa Sulis; Sarah Jenkinson; Christopher G Allen; Rosemary E Gale; David C Linch; Teresa Palomero; Pedro Real; Vundavalli Murty; Xiaopan Yao; Susan M Richards; Anthony Goldstone; Jacob Rowe; Giuseppe Basso; Peter H Wiernik; Elisabeth Paietta; Rob Pieters; Martin Horstmann; Jules P P Meijerink; Adolfo A Ferrando
Journal:  Blood       Date:  2009-06-03       Impact factor: 22.113

3.  Indole-3-carbinol suppresses NF-κB activity and stimulates the p53 pathway in pre-B acute lymphoblastic leukemia cells.

Authors:  Majid Safa; Behnaz Tavasoli; Rima Manafi; Fatemeh Kiani; Meysam Kashiri; Saber Ebrahimi; Ahmad Kazemi
Journal:  Tumour Biol       Date:  2015-01-15

Review 4.  Genomics in acute lymphoblastic leukaemia: insights and treatment implications.

Authors:  Kathryn G Roberts; Charles G Mullighan
Journal:  Nat Rev Clin Oncol       Date:  2015-03-17       Impact factor: 66.675

5.  Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Jinghui Zhang; Charles G Mullighan; Richard C Harvey; Gang Wu; Xiang Chen; Michael Edmonson; Kenneth H Buetow; William L Carroll; I-Ming Chen; Meenakshi Devidas; Daniela S Gerhard; Mignon L Loh; Gregory H Reaman; Mary V Relling; Bruce M Camitta; W Paul Bowman; Malcolm A Smith; Cheryl L Willman; James R Downing; Stephen P Hunger
Journal:  Blood       Date:  2011-06-16       Impact factor: 22.113

6.  TP53 alterations in relapsed childhood acute lymphoblastic leukemia.

Authors:  Chih-Hsiang Yu; Wan-Ting Chang; Shiann-Tarng Jou; Tze-Kang Lin; Ya-Hsuan Chang; Chien-Yu Lin; Kai-Hsin Lin; Meng-Yao Lu; Shu-Huey Chen; Kang-Hsi Wu; Shih-Chung Wang; Hsiu-Hao Chang; Yi-Ning Su; Chia-Cheng Hung; Dong-Tsamn Lin; Hsuan-Yu Chen; Yung-Li Yang
Journal:  Cancer Sci       Date:  2019-12-05       Impact factor: 6.716

7.  Analyzing the gene expression profile of pediatric acute myeloid leukemia with real-time PCR arrays.

Authors:  Tao Yan-Fang; Wu Dong; Pang Li; Zhao Wen-Li; Lu Jun; Wang Na; Wang Jian; Feng Xing; Li Yan-Hong; Ni Jian; Pan Jian
Journal:  Cancer Cell Int       Date:  2012-09-08       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.